Gamma Medica said it has closed on a $16 million series A financing round from healthcare investment firm Psilos Group Managers.
The company said it would use the capital to expand commercialization of its LumaGem molecular breast imaging (MBI) system and companion LumaGuide image-guided biopsy module.
After completing a Chapter 11 bankruptcy process in March 2013, Gamma Medica sold its preclinical imaging division to investment firm Capital Resource Partners, which created Trifoil Imaging to market the systems. The LumaGem MBI unit was sold to Imaging Acquisition, an entity controlled by Psilos, and continues under the Gamma Medica flag.
